Associated tags: Health, Oncology, Biotechnology, Cancer, Pharmaceutical, Disease, Clinical Trials, Security (finance), Momelotinib, Pharmaceutical industry, Doctor of Philosophy, Research, MBBS, Ruxolitinib
Sierra Oncology, Inc. (NASDAQ: SRRA), a late-stage biopharmaceutical company dedicated to delivering targeted therapies for rare cancers, granted stock options to twelve new employees as approved by the Compensation Committee of the Companys Board of Directors, under Sierra Oncologys 2018 Equity Inducement Plan.
Key Points:
- Sierra Oncology, Inc. (NASDAQ: SRRA), a late-stage biopharmaceutical company dedicated to delivering targeted therapies for rare cancers, granted stock options to twelve new employees as approved by the Compensation Committee of the Companys Board of Directors, under Sierra Oncologys 2018 Equity Inducement Plan.
- The 2018 Equity Inducement Plan is used exclusively for the grant of equity awards to individuals as an inducement material to such individuals entering into employment with Sierra, pursuant to Rule 5635(c)(4) of the NASDAQ Listing Rules.
- The employees received options to purchase a total 96,200 shares of Sierras common stock.
- Sierra Oncology is a late-stage biopharmaceutical company on a mission to deliver targeted therapies that treat rare forms of cancer.
Retrieved on:
Wednesday, April 13, 2022
Each stock is evaluated based on short-term technical, long-term technical and fundamental factors.
Key Points:
- Each stock is evaluated based on short-term technical, long-term technical and fundamental factors.
- Each of those scores is then combined into an overall score that determines a stock's overall suitability for investment.
- InvestorsObserver provides patented technology to some of the biggest names on Wall Street and creates world-class investing tools for the self-directed investor on Main Street.
- We have a wide range of tools to help investors make smarter decisions when investing in stocks or options.
Retrieved on:
Wednesday, April 13, 2022
Luke Miels, Chief Commercial Officer, GSK said: Sierra Oncology complements our commercial and medical expertise in haematology.
Key Points:
- Luke Miels, Chief Commercial Officer, GSK said: Sierra Oncology complements our commercial and medical expertise in haematology.
- Sierra Oncology is a late-stage biopharmaceutical company based in San Mateo, California, on a mission to deliver targeted therapies that treat rare forms of cancer.
- This communication is being made in respect of the proposed acquisition of Sierra Oncology, Inc. (Sierra) by GlaxoSmithKline plc (GSK).
- All forward-looking statements are based on information currently available to GSK and Sierra, and neither GSK nor Sierra assumes any obligation to update any forward-looking statements.
Sierra Oncology, Inc. (NASDAQ: SRRA), a late-stage biopharmaceutical company dedicated to delivering targeted therapies for rare cancers, granted stock options to seven new employees as approved by the Compensation Committee of the Companys Board of Directors, under Sierra Oncologys 2018 Equity Inducement Plan.
Key Points:
- Sierra Oncology, Inc. (NASDAQ: SRRA), a late-stage biopharmaceutical company dedicated to delivering targeted therapies for rare cancers, granted stock options to seven new employees as approved by the Compensation Committee of the Companys Board of Directors, under Sierra Oncologys 2018 Equity Inducement Plan.
- The 2018 Equity Inducement Plan is used exclusively for the grant of equity awards to individuals as an inducement material to such individuals entering into employment with Sierra, pursuant to Rule 5635(c)(4) of the NASDAQ Listing Rules.
- The employees received options to purchase a total 55,500 shares of Sierras common stock.
- Sierra Oncology is a late-stage biopharmaceutical company on a mission to deliver targeted therapies that treat rare forms of cancer.
Biotechnology,
Pharmaceutical,
Health,
Oncology,
Event,
Cancer,
NASDAQ,
Conference,
Disease,
Investor,
Doctor of Philosophy,
MBBS,
Pharmaceutical industry Sierra Oncology, Inc. (NASDAQ: SRRA), a late-stage biopharmaceutical company dedicated to delivering targeted therapies for rare cancers, today announced the company will participate in the 32nd Annual Oppenheimer Healthcare Conference being held virtually from March 15-17, 2022.
Key Points:
- Sierra Oncology, Inc. (NASDAQ: SRRA), a late-stage biopharmaceutical company dedicated to delivering targeted therapies for rare cancers, today announced the company will participate in the 32nd Annual Oppenheimer Healthcare Conference being held virtually from March 15-17, 2022.
- President and Chief Executive Officer Stephen Dilly, MBBS, PhD, will provide an overview of the company on Tuesday, March 15, 2022, beginning at 3:20 pm ET.
- A replay of the presentation will be available following the conference on the Investors section of Sierras corporate website in the Events & Webcast tab.
- Sierra Oncology is a late-stage biopharmaceutical company on a mission to deliver targeted therapies that treat rare forms of cancer.
Biotechnology,
Health,
Pharmaceutical,
Clinical Trials,
Oncology,
NASDAQ,
Safety,
Clinical trial,
BRD4,
Exercise,
Private Securities Litigation Reform Act,
Risk,
Name,
Marketing,
JAK,
Research,
Cyprus Securities and Exchange Commission,
Generally Accepted Accounting Principles (United States),
LLC,
Cancer,
AstraZeneca,
Momelotinib,
BET,
NDA,
Ruxolitinib,
GAAP,
Anemia,
Journal,
Doctor of Philosophy,
Patient,
Security (finance),
US Foods,
Hematology,
COVID-19,
Disease,
Review,
Income,
MBBS,
Pharmaceutical industry,
Cryptocurrency,
Bank,
Risk management Sierra Oncology is a late-stage biopharmaceutical company on a mission to deliver targeted therapies that treat rare forms of cancer.
Key Points:
- Sierra Oncology is a late-stage biopharmaceutical company on a mission to deliver targeted therapies that treat rare forms of cancer.
- In addition to operating results as calculated in accordance with GAAP, Sierra Oncology uses certain non-GAAP financial measures when evaluating operational performance.
- Sierra Oncology believes that non-GAAP financial measures should only be used to evaluate its results of operations in conjunction with the corresponding GAAP financial measures.
- Sierra Oncology encourages investors to carefully consider its results under GAAP, as well as the reconciliations between these presentations, to more fully understand its business.
Sierra Oncology, Inc. (NASDAQ: SRRA), a late-stage biopharmaceutical company dedicated to delivering targeted therapies that treat rare forms of cancer, granted stock options to six new employees as approved by the Compensation Committee of the Companys Board of Directors, under Sierra Oncologys 2018 Equity Inducement Plan.
Key Points:
- Sierra Oncology, Inc. (NASDAQ: SRRA), a late-stage biopharmaceutical company dedicated to delivering targeted therapies that treat rare forms of cancer, granted stock options to six new employees as approved by the Compensation Committee of the Companys Board of Directors, under Sierra Oncologys 2018 Equity Inducement Plan.
- The 2018 Equity Inducement Plan is used exclusively for the grant of equity awards to individuals as an inducement material to such individuals entering into employment with Sierra, pursuant to Rule 5635(c)(4) of the NASDAQ Listing Rules.
- The employees received options to purchase a total 43,500 shares of Sierras common stock.
- Sierra Oncology is a late-stage biopharmaceutical company on a mission to deliver targeted therapies that treat rare forms of cancer.
Retrieved on:
Thursday, February 3, 2022
Biotechnology,
Pharmaceutical,
Health,
Oncology,
Cantor,
Public expenditure,
Capital market,
Sale,
Oppenheimer Holdings,
Attention,
Cancer,
SEC,
Telephone,
Exercise,
Form,
Research,
Prospectus,
Jefferies,
Jefferies Group,
Disease,
U.S. Securities and Exchange Commission,
Park Avenue,
Madison Avenue,
Oppenheimer,
Security (finance),
Form S-3,
Nasdaq With this exercise, the aggregate gross proceeds to Sierra Oncology from the offering were approximately $155.3 million, before deducting underwriting discounts and commissions and other offering expenses.
Key Points:
- With this exercise, the aggregate gross proceeds to Sierra Oncology from the offering were approximately $155.3 million, before deducting underwriting discounts and commissions and other offering expenses.
- The offering of the additional 750,000 shares closed on February 3, 2022.
- Jefferies and Cantor acted as the joint book-running managers and representatives of the underwriters for the offering.
- Sierra Oncology is a late-stage biopharmaceutical company on a quest to deliver targeted therapies that treat rare forms of cancer.
Biotechnology,
Pharmaceutical,
Health,
Oncology,
Cantor,
Public expenditure,
Capital market,
Sale,
Oppenheimer Holdings,
Attention,
Cancer,
SEC,
Telephone,
Form,
Research,
Prospectus,
Jefferies,
Jefferies Group,
Disease,
U.S. Securities and Exchange Commission,
Park Avenue,
Madison Avenue,
Oppenheimer,
Security (finance),
Form S-3,
Nasdaq The gross proceeds to Sierra Oncology from the offering were approximately $135.0 million, before deducting underwriting discounts and commissions and other offering expenses.
Key Points:
- The gross proceeds to Sierra Oncology from the offering were approximately $135.0 million, before deducting underwriting discounts and commissions and other offering expenses.
- Net proceeds to Sierra Oncology from the offering were approximately $126.6 million after deducting underwriting discounts and commissions and other offering expenses.
- Jefferies and Cantor are acting as the joint book-running managers and representatives of the underwriters for the offering.
- Sierra Oncology is a late-stage biopharmaceutical company on a quest to deliver targeted therapies that treat rare forms of cancer.
Retrieved on:
Thursday, January 27, 2022
Oncology,
Health,
Clinical Trials,
Research,
Science,
Pharmaceutical,
Biotechnology,
Telephone,
Jefferies Group,
Cantor,
Form S-3,
Capital market,
SEC,
Research,
Prospectus,
Cancer,
Jefferies,
Attention,
Oppenheimer,
Oppenheimer Holdings,
NASDAQ,
Form,
Park Avenue,
Madison Avenue,
Sale,
Public expenditure,
Disease,
Security (finance) The expected gross proceeds to Sierra Oncology from the offering is approximately $135.0 million, before deducting underwriting discounts and commissions and other offering expenses.
Key Points:
- The expected gross proceeds to Sierra Oncology from the offering is approximately $135.0 million, before deducting underwriting discounts and commissions and other offering expenses.
- In addition, Sierra Oncology has granted to the underwriters a 30-day option to purchase up to 750,000 of additional shares of its common stock at the public offering price less underwriting discounts and commissions.
- All of the securities are being offered by Sierra Oncology.
- Sierra Oncology is a late-stage biopharmaceutical company on a quest to deliver targeted therapies that treat rare forms of cancer.
